Product nameAnti-Neurofibromin antibody
See all Neurofibromin primary antibodies
DescriptionRabbit polyclonal to Neurofibromin
Tested applicationsSuitable for: WB, IHC-P, ICC/IF, ELISAmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse, Rat
Synthetic peptide, corresponding to an internal region of Human Neurofibromin.
- HepG2 cell extract, Human spleen and Human tonsil tissues, HepG2 cells
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 49% PBS, 50% Glycerol, 0.88% Sodium chloride
Note: (without Mg2+, Ca2+)
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab128054 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500 - 1/1000. Predicted molecular weight: 319 kDa.|
|IHC-P||1/100. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
|ICC/IF||1/100 - 1/500.|
FunctionStimulates the GTPase activity of Ras. NF1 shows greater affinity for Ras GAP, but lower specific activity. May be a regulator of Ras activity.
Involvement in diseaseDefects in NF1 are the cause of neurofibromatosis type 1 (NF1) [MIM:162200]; also known as von Recklinghausen syndrome. A disease characterized by patches of skin pigmentation (cafe-au-lait spots), Lisch nodules of the iris, tumors in the peripheral nervous system and fibromatous skin tumors. Individuals with the disorder have increased susceptibility to the development of benign and malignant tumors.
Defects in NF1 are a cause of juvenile myelomonocytic leukemia (JMML) [MIM:607785]. JMML is a pediatric myelodysplastic syndrome that constitutes approximately 30% of childhood cases of myelodysplastic syndrome (MDS) and 2% of leukemia. Germline mutations of NF1 account for the association of JMML with type 1 neurofibromatosis (NF1).
Defects in NF1 are the cause of Watson syndrome (WS) [MIM:193520]. WS is characterized by the presence of pulmonary stenosis, cafe-au-lait spots, and mental retardation. WS is considered as an atypical form of NF1.
Defects in NF1 are a cause of familial spinal neurofibromatosis (FSNF) [MIM:162210]. Familial spinal NF is considered to be an alternative form of neurofibromatosis, showing multiple spinal tumors.
Defects in NF1 are a cause of neurofibromatosis-Noonan syndrome (NFNS) [MIM:601321]. NFNS is characterized by manifestations of both NF1 and Noonan syndrome (NS). NS is a disorder characterized by dysmorphic facial features, short stature, hypertelorism, cardiac anomalies, deafness, motor delay, and a bleeding diathesis.
Defects in NF1 may be a cause of colorectal cancer (CRC) [MIM:114500].
Sequence similaritiesContains 1 CRAL-TRIO domain.
Contains 1 Ras-GAP domain.
- Information by UniProt
- DKFZp686J1293 antibody
- FLJ21220 antibody
- Neurofibromatosis Noonan syndrome antibody
All lanes : Anti-Neurofibromin antibody (ab128054) at 1/500 dilution
Lane 1 : HepG2 cells extract
Lane 2 : HepG2 cells extract with synthesized peptide
Predicted band size: 319 kDa
ab128054, at a dilution of 1/100, staining Neurofibromin in paraffin-embedded Human spleen tissue by Immunohistochemistry.
ab128054, at a dilution of 1/100, staining Neurofibromin in paraffin-embedded Human tonsil tissue by Immunohistochemistry.
ab128054, at a dilution of 1/100, staining Neurofibromin in HepG2 cells by Immunofluorescence. The picture on the right is treated with the synthesized peptide.
ab128054 has not yet been referenced specifically in any publications.